Today we presented new Phase 1 Data for our folate receptor alpha-targeting antibody-drug conjugate at #AACR26. The ADC demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression.

“We are highly encouraged by the initial clinical data for ZW191, which reinforce the strength of our ADC platform and its ability to generate differentiated therapeutics. The breadth and durability of responses, along with activity across varying levels of FRα expression, support further development of ZW191 as a potential best-in-class agent for patients with ovarian and endometrial cancers.” - Dr. Sabeen Mekan, SVP and Chief Medical Officer.

View the presentation: https://t.co/DbDY5YRst2

Read our press release: https://t.co/Q7hoFzpXKa